Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ICN Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: IRWIN JAMES FRANKEL who wrote (800)	3/30/1998 2:44:00 PM
From: L.A.	Respond to of 1029

ICN HAS NOT CHANGED (JUST THE ANALYST) THEY ALSO DROPPED PFE, SGP, ELI LILLY, BMY, & SEVERAL OTHER ONE'S. L.A.

To: IRWIN JAMES FRANKEL who wrote (800)	9/28/1998 9:34:00 PM
From: Robohogs	Read Replies (1) \| Respond to of 1029

OT OT OT IJ - I am now beginning to give up hope for our favorite little friend. Yes, I believe earnings will be above $3 per share next year, but the market cannot be this dumb. I want to buy more shares in here (near my average cost after averaging up) but I just have too much in this one. Any other ideas you're looking at? I know you once owned ASND - have you looked at COMS in here? Looks cheap. Good luck. Let's hope our ICN plays out, but I'm now diversifying away from ICN - now only 15% of my porfolio down from 33%. ASND (takeout by LU looming at $65), CNTO (RA approval will yield $55 with a PE of 5x ICN's PE), ELN (PE moving ever higher) and APOS (a true future homerun) now dominate that portfolio with COMS growing. Only time will tell.